|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||N/A|
Jazz Pharmaceuticals (JAZZ) expects quarterly variability in Defitelio sales as the drug targets hepatic veno-occlusive disease (or VOD), an ultra-rare condition.
Defitelio could help Jazz Pharmaceuticals become a prominent player not only in the treatment but also in the prevention of post-HSCT complications.
For 2Q17, Jazz Pharmaceuticals (JAZZ) reported revenues close to $394 million, which represented a YoY growth of ~3% and sequential growth ~5%.